ABSCINT specializes in advanced in vivo imaging diagnostics, focusing on developing innovative PET tracers using single-domain antibodies (sdAbs) for precision targeting. ABSCINT’s primary product is a specific anti-HER2 PET tracer, which enables comprehensive whole-body imaging for evaluating disease heterogeneity in HER2-low and HER2-positive breast cancer. This non-invasive technology offers rapid imaging results within 90 minutes, with minimal radiation exposure. This innovation also opens the door to HER2 reclassification via image-guided biopsies, enhancing diagnostic accuracy, patient care, and monitoring of treatment efficacy.
-- ABSCINT, Harnessing Antibody Scintigraphy for Precision Diagnostics in Breast Cancer and Beyond --
Company Details
- Employees
- 12
- Founded
- -
- Address
- Boulevard Patience Et Beaujonc 3, Liège,4000,belgium
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://abscint.com
- HQ
- Liège
Abscint Questions
Abscint's website is https://abscint.com
Abscint's LinkedIn profile is https://be.linkedin.com/company/abscint
Abscint has
12 employees.
View email and phone details for 12
employees at Abscint.
Abscint's industry is
Biotechnology Research
Abscint's top competitors are
Exo Biologics,
Trasis,
Amyl Therapeutics,
Bioxodes,
Theratrame,
Conveyxo,
Novadip Biosciences S.a.,
Diasource Immunoassays,
Esobiotec,
Pdc*line Pharma.
Abscint's categories are Biotechnology Research
Abscint's founding year is 2020
